RU2018104092A3 - - Google Patents

Info

Publication number: RU2018104092A3
Authority: RU; Russia

Application number

RU2018104092A

Other versions

RU2018104092A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-02

Filing date

2016-07-01

Publication date

2019-08-05

2016-07-01 Application filed filed Critical

2019-08-05 Publication of RU2018104092A publication Critical patent/RU2018104092A/ru

2019-08-05 Publication of RU2018104092A3 publication Critical patent/RU2018104092A3/ru

2020-03-06 Application granted granted Critical

2020-03-06 Publication of RU2716136C2 publication Critical patent/RU2716136C2/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RU2018104092A 2015-07-02 2016-07-01 Бициклические лактамы и способы их применения RU2716136C2 (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562188153P	2015-07-02	2015-07-02
US62/188,153		2015-07-02
US201562387295P	2015-12-23	2015-12-23
US62/387,295		2015-12-23
PCT/US2016/040659 WO2017004500A1 (en)	2015-07-02	2016-07-01	Bicyclic lactams and methods of use thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2020106140A Division RU2827714C1 (ru)	2015-07-02	2016-07-01	Бициклические лактамы и способы их применения

Publications (3)

Publication Number	Publication Date
RU2018104092A RU2018104092A (ru)	2019-08-05
RU2018104092A3 true RU2018104092A3 (ru)	2019-08-05
RU2716136C2 RU2716136C2 (ru)	2020-03-06

Family

ID=56411952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018104092A RU2716136C2 (ru)	2015-07-02	2016-07-01	Бициклические лактамы и способы их применения

Country Status (24)

Country	Link
US (2)	US10988459B2 (ru)
EP (2)	EP3760625B1 (ru)
JP (2)	JP6785252B2 (ru)
KR (2)	KR102603915B1 (ru)
CN (3)	CN112979660A (ru)
AU (4)	AU2016287581B2 (ru)
CA (2)	CA2988601C (ru)
CL (2)	CL2017003486A1 (ru)
CO (1)	CO2017013709A2 (ru)
CR (1)	CR20170573A (ru)
ES (1)	ES2930749T3 (ru)
IL (2)	IL255830B (ru)
MA (2)	MA53835A (ru)
MX (2)	MX380753B (ru)
MY (1)	MY192762A (ru)
PE (2)	PE20221048A1 (ru)
PH (1)	PH12018500034A1 (ru)
PL (1)	PL3317269T3 (ru)
RU (1)	RU2716136C2 (ru)
SG (1)	SG10201913880XA (ru)
TW (2)	TWI788830B (ru)
UA (1)	UA122150C2 (ru)
WO (1)	WO2017004500A1 (ru)
ZA (1)	ZA201707812B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3760625B1 (en)	2015-07-02	2024-03-27	F. Hoffmann-La Roche AG	Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
WO2017069279A1 (ja) *	2015-10-23	2017-04-27	武田薬品工業株式会社	複素環化合物
WO2017109724A1 (en) *	2015-12-21	2017-06-29	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
AU2017213628B2 (en)	2016-02-05	2021-07-29	Denali Therapeutics Inc.	Inhibitors of receptor-interacting protein kinase 1
EP3526219B1 (en)	2016-10-17	2021-12-15	F. Hoffmann-La Roche AG	Bicyclic pyridone lactams and methods of use thereof
US11071721B2 (en)	2016-12-02	2021-07-27	Genentech, Inc.	Bicyclic amide compounds and methods of use thereof
WO2018107060A1 (en)	2016-12-09	2018-06-14	Denali Therapeutics Inc.	Compounds, compositions and methods
US11072607B2 (en) *	2016-12-16	2021-07-27	Genentech, Inc.	Inhibitors of RIP1 kinase and methods of use thereof
JP2020509009A (ja)	2017-02-27	2020-03-26	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	キナーゼ阻害剤としての複素環式アミド
GB201706102D0 (en) *	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN107200737B (zh) *	2017-06-29	2019-03-26	武汉药明康德新药开发有限公司	叔丁氧羰基-3-(羟甲基)-[1,2,3]三氮唑[1,5-a]哌啶-6-酰胺制法
KR102664604B1 (ko) *	2017-07-14	2024-05-14	에프. 호프만-라 로슈 아게	이환형 케톤 화합물 및 이의 사용 방법
SG11202003283TA (en) *	2017-10-11	2020-05-28	Hoffmann La Roche	Bicyclic compounds for use as rip1 kinase inhibitors
WO2019086494A1 (en) *	2017-10-31	2019-05-09	F. Hoffmann-La Roche Ag	Bicyclic sulfones and sulfoxides and methods of use thereof
WO2019204537A1 (en)	2018-04-20	2019-10-24	Genentech, Inc.	N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
PE20210414A1 (es)	2018-05-03	2021-03-04	Rigel Pharmaceuticals Inc	Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
DK3788044T3 (da)	2018-05-03	2023-10-02	Rigel Pharmaceuticals Inc	RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
CA3104757A1 (en) *	2018-06-26	2020-01-02	Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences	Cell necrosis inhibitor, preparation method therefor and use thereof
CN110642874B (zh) *	2018-06-26	2023-03-28	中国科学院上海有机化学研究所	一类细胞坏死抑制剂及其制备方法和用途
WO2020044206A1 (en)	2018-08-29	2020-03-05	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors for use in the treatment cancer
SG11202101632XA (en) *	2018-09-10	2021-03-30	Kaken Pharmaceutical Co Ltd	Novel heteroaromatic amide derivative and medicine containing same
CN109134448B (zh) *	2018-10-16	2020-11-27	中南大学湘雅医院	杂环化合物及其盐、制备方法、用途和药物
TW202043229A (zh)	2019-01-11	2020-12-01	瑞士商赫孚孟拉羅股份公司	雙環酮化合物及其使用方法
SG11202108064XA (en) *	2019-01-25	2021-08-30	Beijing Scitech Mq Pharmaceuticals Ltd	Acylamino bridged heterocyclic compound, and composition and application thereof
AR118243A1 (es)	2019-03-07	2021-09-22	Pi Industries Ltd	Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas
JP7299350B2 (ja) *	2019-05-31	2023-06-27	メッドシャインディスカバリーインコーポレイテッド	Ｒｉｐ－１キナーゼ阻害剤としての二環式化合物およびその使用
CN110183442A (zh) *	2019-06-06	2019-08-30	无锡合全药业有限公司	一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
PE20221628A1 (es)	2019-09-06	2022-10-19	Rigel Pharmaceuticals Inc	Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
US20220289692A1 (en) *	2019-09-06	2022-09-15	Inflazome Limited	Nlrp3 inhibitors
US11718612B2 (en)	2019-09-06	2023-08-08	Board Of Regents, The University Of Texas System	Inhibitors of receptor interacting protein kinase I for the treatment of disease
TW202122397A (zh)	2019-09-06	2021-06-16	美商雷傑製藥公司	Ｒｉｐ１抑制性化合物及用於製備和使用其之方法
IL291665B2 (en)	2019-09-27	2025-07-01	Univ Texas	Inhibitors of receptor interacting protein kinase i for the treatment of disease
MX2022005509A (es)	2019-11-07	2022-10-18	Rigel Pharmaceuticals Inc	Compuestos inhibidores de rip1 heterociclicos.
CA3162605A1 (en) *	2019-11-26	2021-06-03	Board Of Regents, The University Of Texas System	Inhibitors of receptor interacting protein kinase i for the treatment of disease
PE20221916A1 (es)	2019-12-20	2022-12-23	Pfizer	Compuestos quimicos
JP7701162B2 (ja) *	2020-02-28	2025-07-01	科研製薬株式会社	新規ヘテロ芳香族アミド誘導体又はその塩からなる医薬
IL295975A (en) *	2020-02-28	2022-10-01	Univ Texas	Inhibitors of receptor interacting protein kinase i for the treatment of disease
AR121717A1 (es)	2020-04-02	2022-06-29	Rigel Pharmaceuticals Inc	Inhibidores de rip1k
JP7477642B2 (ja)	2020-04-09	2024-05-01	ディスアームセラピューティクス，インコーポレイテッド	Ｓａｒｍ１の阻害剤
WO2021233861A1 (en)	2020-05-19	2021-11-25	Bayer Aktiengesellschaft	Azabicyclic(thio)amides as fungicidal compounds
EP4165038A1 (en)	2020-06-10	2023-04-19	Bayer Aktiengesellschaft	Azabicyclyl-substituted heterocycles as fungicides
TWI840311B (zh)	2020-07-01	2024-04-21	美商雷傑製藥公司	Rip1k抑制劑
EP3974414A1 (de)	2020-09-25	2022-03-30	Bayer AG	5-amino substituierte pyrazole und triazole als schädlingsbekämpfungsmittel
WO2022171111A1 (en) *	2021-02-10	2022-08-18	Zai Lab (Us) Llc	Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof
WO2022171110A1 (en) *	2021-02-10	2022-08-18	Zai Lab (Us) Llc	Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof
TW202300490A (zh) *	2021-03-11	2023-01-01	美商雷傑製藥公司	雜環rip1激酶抑制劑
TW202304921A (zh)	2021-04-02	2023-02-01	美商建南德克公司	製造雙環酮化合物之方法
CN113651810B (zh) *	2021-07-16	2023-10-13	上海毕得医药科技股份有限公司	一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法
JP7406672B2 (ja)	2021-08-10	2023-12-27	アッヴィ・インコーポレイテッド	ニコチンアミド系ｒｉｐｋ１阻害剤
WO2023020486A1 (zh) *	2021-08-17	2023-02-23	广州市恒诺康医药科技有限公司	Rip1激酶抑制剂类化合物及其组合物和用途
US20230060797A1 (en) *	2021-09-02	2023-03-02	Jcr Pharmaceuticals Co., Ltd.	Therapeutic compound for neuronal ceroid lipofuscinosis
WO2023119210A1 (ko)	2021-12-24	2023-06-29	제일약품주식회사	Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
EP4463229A1 (en)	2022-01-12	2024-11-20	Denali Therapeutics Inc.	Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
TW202345852A (zh)	2022-03-16	2023-12-01	大陸商江蘇恆瑞醫藥股份有限公司	稠雜環類化合物、其製備方法及其在醫藥上的應用
WO2023240379A1 (zh) *	2022-06-13	2023-12-21	南京医工医药技术有限公司	咪唑啉酮衍生物及其用途
WO2024013736A1 (en) *	2022-07-12	2024-01-18	Adama Makhteshim Ltd.	Process for preparing substituted benzamides
CN118084889B (zh) *	2024-01-16	2024-09-27	宁夏医科大学	吲哚3-芳基-5-甲酰胺类衍生物及用途
CN119684191A (zh) *	2025-01-22	2025-03-25	中国科学技术大学	一种可见光催化合成β-内酰胺和双环[2,1,1]化合物的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206234A (en)	1990-10-22	1993-04-27	Merck & Co., Inc.	Benzolactam analogs as antagonists of cck
ATE346085T1 (de)	1996-12-06	2006-12-15	Vertex Pharma	Inhibitoren des interleukin-1-beta konvertierenden enzyms
GB0021831D0 (en) *	2000-09-06	2000-10-18	Astrazeneca Ab	Chemical compounds
US20030113782A1 (en)	2001-11-26	2003-06-19	Karim Felix D.	MAP4Ks as modifiers of branching morphogenesis and methods of use
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
CA2502685A1 (en)	2002-10-23	2004-05-06	Exelixis, Inc.	Cdkl1 as modifier of branching morphogenesis and methods of use
US7390798B2 (en)	2004-09-13	2008-06-24	Merck & Co., Inc.	Carboxamide spirolactam CGRP receptor antagonists
RU2281947C1 (ru)	2005-07-05	2006-08-20	Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия"	Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
EP1966244B1 (en)	2005-12-30	2012-03-21	Merck Patent GmbH	Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
DE602007006961D1 (de)	2006-07-21	2010-07-15	Vertex Pharma	Cgrp-rezeptorantagonisten
WO2009140128A2 (en)	2008-05-13	2009-11-19	Irm Llc	Compounds and compositions as kinase inhibitors
US20130018039A1 (en) *	2010-03-31	2013-01-17	Bodmer Vera Q	Imidazolyl-imidazoles as kinase inhibitors
GB201106817D0 (en) *	2011-04-21	2011-06-01	Astex Therapeutics Ltd	New compound
TWI549944B (zh)	2011-07-01	2016-09-21	吉李德科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
US20140357570A1 (en)	2011-10-21	2014-12-04	Massachusetts Eye And Ear Infirmary	Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
BR112015000649A2 (pt)	2012-07-13	2017-06-27	Hoffmann La Roche	compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção
MX2015001720A (es)	2012-08-09	2015-04-14	Hoffmann La Roche	Hetero-azepinonas sustituidas.
TWI638815B (zh) *	2013-02-15	2018-10-21	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺類（一）
US20160024098A1 (en)	2013-03-15	2016-01-28	President And Fellows Of Harvard College	Hybrid necroptosis inhibitors
US20160051629A1 (en)	2013-04-15	2016-02-25	Yeda Research And Development Co. Ltd.	Inhibition of rip kinases for treating lysosomal storage diseases
WO2016027253A1 (en)	2014-08-21	2016-02-25	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as rip1 kinase inhibitors as medicaments
PL3316969T3 (pl)	2015-07-02	2022-06-20	Janssen Sciences Ireland Unlimited Company	Związki przeciwbakteryjne
KR20170004814A (ko)	2015-07-02	2017-01-11	주식회사 녹십자	헌터증후군 치료제
EP3760625B1 (en)	2015-07-02	2024-03-27	F. Hoffmann-La Roche AG	Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
MA49861A (fr)	2015-07-02	2021-05-05	Hoffmann La Roche	Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108602809B (zh)	2015-12-04	2022-09-30	戴纳立制药公司	异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US20210238162A1 (en)	2015-12-17	2021-08-05	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds
WO2017109724A1 (en)	2015-12-21	2017-06-29	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
KR20180095051A (ko)	2015-12-23	2018-08-24	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	코르티스타틴 유사체 및 그의 용도
AU2017213628B2 (en)	2016-02-05	2021-07-29	Denali Therapeutics Inc.	Inhibitors of receptor-interacting protein kinase 1
EP3526219B1 (en)	2016-10-17	2021-12-15	F. Hoffmann-La Roche AG	Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en)	2016-12-16	2021-07-27	Genentech, Inc.	Inhibitors of RIP1 kinase and methods of use thereof
WO2019204537A1 (en)	2018-04-20	2019-10-24	Genentech, Inc.	N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
PE20221628A1 (es) *	2019-09-06	2022-10-19	Rigel Pharmaceuticals Inc	Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
AR121717A1 (es) *	2020-04-02	2022-06-29	Rigel Pharmaceuticals Inc	Inhibidores de rip1k

2016
- 2016-07-01 EP EP20169511.1A patent/EP3760625B1/en active Active
- 2016-07-01 MA MA053835A patent/MA53835A/fr unknown
- 2016-07-01 PE PE2022000233A patent/PE20221048A1/es unknown
- 2016-07-01 KR KR1020197037917A patent/KR102603915B1/ko active Active
- 2016-07-01 AU AU2016287581A patent/AU2016287581B2/en active Active
- 2016-07-01 TW TW110115743A patent/TWI788830B/zh active
- 2016-07-01 US US15/200,058 patent/US10988459B2/en active Active
- 2016-07-01 UA UAA201800850A patent/UA122150C2/uk unknown
- 2016-07-01 CA CA2988601A patent/CA2988601C/en active Active
- 2016-07-01 CN CN202110232427.4A patent/CN112979660A/zh active Pending
- 2016-07-01 CR CR20170573A patent/CR20170573A/es unknown
- 2016-07-01 CN CN202010119812.3A patent/CN111269221B/zh active Active
- 2016-07-01 KR KR1020187003088A patent/KR102104911B1/ko active Active
- 2016-07-01 PL PL16738985.7T patent/PL3317269T3/pl unknown
- 2016-07-01 SG SG10201913880XA patent/SG10201913880XA/en unknown
- 2016-07-01 CA CA3094197A patent/CA3094197C/en active Active
- 2016-07-01 MY MYPI2019006777A patent/MY192762A/en unknown
- 2016-07-01 PE PE2017002860A patent/PE20180501A1/es unknown
- 2016-07-01 TW TW105120997A patent/TWI763630B/zh active
- 2016-07-01 MX MX2017016482A patent/MX380753B/es unknown
- 2016-07-01 MA MA042302A patent/MA42302A/fr unknown
- 2016-07-01 WO PCT/US2016/040659 patent/WO2017004500A1/en not_active Ceased
- 2016-07-01 EP EP16738985.7A patent/EP3317269B1/en active Active
- 2016-07-01 ES ES16738985T patent/ES2930749T3/es active Active
- 2016-07-01 CN CN201680039261.1A patent/CN107849023B/zh active Active
- 2016-07-01 JP JP2017568057A patent/JP6785252B2/ja active Active
- 2016-07-01 RU RU2018104092A patent/RU2716136C2/ru active
2017
- 2017-11-17 ZA ZA2017/07812A patent/ZA201707812B/en unknown
- 2017-11-21 IL IL255830A patent/IL255830B/en active IP Right Grant
- 2017-12-15 MX MX2021002978A patent/MX2021002978A/es unknown
- 2017-12-28 CO CONC2017/0013709A patent/CO2017013709A2/es unknown
- 2017-12-29 CL CL2017003486A patent/CL2017003486A1/es unknown
2018
- 2018-01-03 PH PH12018500034A patent/PH12018500034A1/en unknown
2019
- 2019-05-16 AU AU2019203444A patent/AU2019203444B2/en active Active
2020
- 2020-05-03 IL IL274391A patent/IL274391B/en unknown
- 2020-10-26 JP JP2020179045A patent/JP7190471B2/ja active Active
- 2020-11-19 CL CL2020003007A patent/CL2020003007A1/es unknown
2021
- 2021-03-10 US US17/198,238 patent/US12281101B2/en active Active
- 2021-04-20 AU AU2021202398A patent/AU2021202398A1/en not_active Abandoned
2022
- 2022-11-29 AU AU2022279425A patent/AU2022279425A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW202130636A (zh)	2021-08-16
MY192762A (en)	2022-09-07
RU2716136C2 (ru)	2020-03-06
CN107849023B (zh)	2021-03-23
JP2021020946A (ja)	2021-02-18
IL274391A (en)	2020-06-30
US10988459B2 (en)	2021-04-27
AU2016287581A9 (en)	2018-03-15
MX2017016482A (es)	2018-03-08
WO2017004500A9 (en)	2017-11-30
UA122150C2 (uk)	2020-09-25
KR20190143848A (ko)	2019-12-31
EP3760625B1 (en)	2024-03-27
EP3760625C0 (en)	2024-03-27
JP7190471B2 (ja)	2022-12-15
NZ770222A (en)	2024-05-31
CN111269221B (zh)	2023-09-26
NZ737297A (en)	2024-03-22
TW201716394A (zh)	2017-05-16
CL2017003486A1 (es)	2018-08-03
AU2022279425A1 (en)	2023-01-19
AU2016287581B2 (en)	2019-06-06
CA3094197A1 (en)	2017-01-05
PE20221048A1 (es)	2022-06-30
CR20170573A (es)	2018-02-20
ES2930749T3 (es)	2022-12-21
IL255830B (en)	2021-02-28
EP3317269A1 (en)	2018-05-09
PL3317269T3 (pl)	2023-01-02
TWI763630B (zh)	2022-05-11
AU2016287581A1 (en)	2017-12-07
AU2021202398A1 (en)	2021-05-20
CN112979660A (zh)	2021-06-18
PE20180501A1 (es)	2018-03-09
MX380753B (es)	2025-04-01
IL255830A (en)	2018-01-31
EP3317269B1 (en)	2022-09-21
CN111269221A (zh)	2020-06-12
US12281101B2 (en)	2025-04-22
US20170008877A1 (en)	2017-01-12
CA3094197C (en)	2023-02-28
KR102603915B1 (ko)	2023-11-21
JP6785252B2 (ja)	2020-11-18
MA42302A (fr)	2018-05-09
EP3760625A1 (en)	2021-01-06
CA2988601C (en)	2021-12-07
CL2020003007A1 (es)	2021-10-01
MX2021002978A (es)	2021-05-14
AU2019203444B2 (en)	2021-01-21
IL274391B (en)	2022-02-01
JP2018519319A (ja)	2018-07-19
RU2018104092A (ru)	2019-08-05
PH12018500034A1 (en)	2018-07-09
TWI788830B (zh)	2023-01-01
HK1251899A1 (zh)	2019-04-26
KR20180023988A (ko)	2018-03-07
ZA201707812B (en)	2024-02-28
BR112018000080A2 (pt)	2018-08-28
CA2988601A1 (en)	2017-01-05
KR102104911B1 (ko)	2020-04-28
CO2017013709A2 (es)	2018-03-28
CN107849023A (zh)	2018-03-27
US20220348559A1 (en)	2022-11-03
SG10201913880XA (en)	2020-03-30
MA53835A (fr)	2021-08-11
AU2019203444A1 (en)	2019-06-06
WO2017004500A1 (en)	2017-01-05

Publication	Publication Date	Title
RU2018104092A3 (ru)	2019-08-05
BR112018005502A2 (ru)	2018-10-02
BR112018002687A2 (ru)	2018-10-02
BR0306322B1 (ru)	2015-10-06
BR0003166B1 (ru)	2015-08-25
BR0007747B1 (ru)	2015-06-02
BR0007688B1 (ru)	2015-06-16
BR0007672B1 (ru)	2015-03-31
BR0007487B1 (ru)	2015-07-07
BR0007468B1 (ru)	2015-08-25
BR0006866B1 (ru)	2015-09-01
BR0006854B1 (ru)	2015-06-16
BR0003189B1 (ru)	2015-03-24
BR0002874B1 (ru)	2015-09-01
BR0002802B1 (ru)	2015-03-31
BR0002694B1 (ru)	2015-08-04
BR0002435B1 (ru)	2015-05-19
BR0002402B1 (ru)	2015-08-11
BR0002033B1 (ru)	2015-06-09
BR0006634B1 (ru)	2015-06-02
BR0001810B1 (ru)	2015-06-23
BR0005085B1 (ru)	2015-06-09
BR0005041B1 (ru)	2015-08-11
BR0001684B1 (ru)	2015-04-22
BR0004687B1 (ru)	2015-05-05